Tag: CERVINO
-
AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.